Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326586 · ClinicalTrials.gov registry record · Phase 1
A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00326586 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 54 participants.
The verdict
NCT00326586, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.
Interventions
- DRUG AR Antagonist (BMS-641988)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326586
The ClinicalTrials.gov registry entry for NCT00326586 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AR Antagonist (BMS-641988) is the first listed.
NCT00326586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00326586 about?
NCT00326586 is a clinical study titled "A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer". This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.
What is the current status of trial NCT00326586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2006-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00326586?
The interventions under investigation include: AR Antagonist (BMS-641988) (DRUG).
Who is sponsoring clinical trial NCT00326586?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.